SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-174586"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-174586" > Expression of ghrel...

Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer

Grönberg, Malin, (författare)
Uppsala universitet, Institutionen för medicinska vetenskaper, Onkologisk endokrinologi
Fjällskog, Marie-Louise, (författare)
Uppsala universitet, Enheten för onkologi
Jirström, Karin (författare)
visa fler...
Tiensuu Janson, Eva, (författare)
Uppsala universitet, Institutionen för medicinska vetenskaper, Onkologisk endokrinologi
Gronberg, Malin (författare)
Fjallskog, Marie-Louise (författare)
Janson, Eva T. (författare)
visa färre...
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet. Medicinska fakulteten. Institutionen för medicinska vetenskaper. (creator_code:org_t)
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet. Medicinska fakulteten. Institutionen för radiologi, onkologi och strålningsvetenskap. Enheten för onkologi. (creator_code:org_t)
2012
Engelska.
Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 51:3, s. 386-393
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background. Expression of the peptide hormones ghrelin and obestatin has previously been demonstrated in human mammary glands. However, the clinical implications of the expression of these peptides in breast cancer are unclear. The aim of this study was to investigate the potential clinical value of ghrelin and obestatin as breast cancer biomarkers. Methods. A tissue microarray containing breast cancer specimens from 144 patients was immunostained with antibodies directed towards ghrelin and obestatin. Using varying cut-offs, the expression of the two peptides was evaluated and correlated to previously known prognostic factors in breast cancer and to the outcome. Cox regression analysis was used to assess whether these markers may predict survival of breast cancer patients. Results. Moderate to strong immunoreactivity for ghrelin and obestatin was observed in 71.5% and 77.1% of the cases, respectively. Ghrelin and obestatin expression was significantly but weakly correlated to low histological grade, estrogen receptor positivity, small tumor size and low proliferation. Only ghrelin expression was significantly correlated to better recurrence-free and breast cancer-specific survival (HR = 0.3-0.4, p = 0.02-0.05) in both uni- and multivariate analyses. The optimal cut-off was any ghrelin expression versus none. Reproducibility between the two readers was very good for both stainings with kappa values of 0.94-1.00. Conclusions. Patients with tumors expressing ghrelin had 2.5-3 times lower risk for recurrence or breast cancer death than those lacking ghrelin expression. Ghrelin expression is easily assessable with high reproducibility using immunohistochemistry. Further investigations are needed to establish the clinical significance of ghrelin as a biomarker in breast cancer.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy